A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

NCT05944224 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: SPH4336
DRUG: Cadonilimab

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd